Minimising the harms of Polypharmacy; Cluster summary of learning points and actions Learning point themes Specific No. of cases Actions Actions learning with these prompted prompted points themes at practice at cluster identified (expressed as level level fraction of the per case medication reviews – e.g. Need and Indication 4/15) Open Questions (patient compliance) Testing and Monitoring Evidence and Guidelines Adverse Events Risk Reduction or prevention Simplification or Switching Other themes not covered above Here the practice may identify issues not covered in the grouped themes above Learning point themes Specific No. of cases Actions Actions learning with these prompted prompted points themes at practice at cluster identified (expressed as level level per case fraction of the medication reviews – e.g. 4/15) e.g. Particular problem drugs noted
Minimising the harms of Polypharmacy; Cluster summary of learning points and actions Learning point themes Specific learning points identified per case No. of cases with these themes (expressed as fraction of the medication reviews – e.g. 4/15) Actions prompted at practice level Actions prompted at cluster level Need and Indication Open Questions (patient compliance) Testing and Monitoring Evidence and Guidelines Adverse Events Risk Reduction or prevention Simplification or Switching Other themes not covered above Here the practice may identify issues not covered in the grouped themes above Learning point themes Specific learning points identified per case No. of cases with these themes (expressed as fraction of the medication reviews – e.g. 4/15) Actions prompted at practice level Actions prompted at cluster level e.g. Particular problem drugs noted
5FinalPolypharmacyGuidance%202015.docx